Aeras & CNBG Ink R&D Pact for TB Vaccine

Multiple research institutes operating under the umbrella of CNBG will engage with Aeras on a strategy focused on the joint development, manufacturing and distribution of affordable new TB vaccines for use globally.

Maryland-based non-profit product development organization Aeras and the China National Biotec Group (CNBG) have reached final agreement to jointly develop new tuberculosis (TB) vaccines.

Multiple research institutes operating under the umbrella of CNBG will engage with Aeras on a strategy focused on the joint development, manufacturing and distribution of affordable new TB vaccines for use globally. The agreement spans all aspects of TB vaccine development – from vaccine discovery to pre-clinical research to clinical research to manufacturing – and positions CNBG as a major emerging player in the TB vaccine field.

Bacille Calmette-Guerin (BCG), the only currently-licensed TB vaccine, does not prevent pulmonary TB, the most common form of the disease. As part of this collaboration, Aeras will license